NCT06801652 is a clinical trial of Sperm morphology indexes in Spermatozoa, Abnormal, sponsored by Calla IVF Center.

Who is sponsoring NCT06801652?

NCT06801652 is sponsored by Calla IVF Center.

What drugs are being tested in NCT06801652?

Interventions in NCT06801652: Sperm morphology indexes.

What condition does NCT06801652 study?

NCT06801652 studies Spermatozoa, Abnormal, in Vitro Fertilization, Blastocyst, Aneuploidy.

Is NCT06801652 still recruiting?

NCT06801652 is currently completed. Last updated 30 January 2025.

Last reviewed 2025-01-30 · How we verify

NCT06801652

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Influence of Sperm Morphology and Functional Indices on Blastocyst Development in Assisted Reproduction

Completed Last updated 30 January 2025

What this trial tests

trial testing Sperm morphology indexes in Spermatozoa, Abnormal in 120 participants. Completed in 10 November 2024.

Timeline

21 October 2023

Primary endpoint
23 October 2024

10 November 2024

Quick facts

Lead sponsor	Calla IVF Center
Status	Completed
Study type	OBSERVATIONAL
Enrollment	120
Start date	21 October 2023
Primary completion	23 October 2024
Estimated completion	10 November 2024
Sites	1 location across Romania

Drugs / interventions tested

Sperm morphology indexes

Conditions studied

Spermatozoa, Abnormal — all drugs for Spermatozoa, Abnormal →
in Vitro Fertilization — all drugs for in Vitro Fertilization →
Blastocyst — all drugs for Blastocyst →
Aneuploidy — all drugs for Aneuploidy →

Sponsor

Calla IVF Center

Who can join

Adults 21 to 40, any sex, with Spermatozoa, Abnormal or in Vitro Fertilization. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Samples from male partners of 120 infertile couples undergoing IVF were analyzed. Sperm morphology was assessed using the SpermBlue staining method, while TZI, MAI, and SDI were calculated. Embryo development was monitored until day 5 or 6. Statistical analyses included regression models and correlation coefficients to evaluate the predictive value of sperm indices on blastocyst development.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Calla IVF Center trials

Trials by the same sponsor.

NCT06795984 — Is There a Correlation Between Endometrial CD56 Levels and the Unfavorable KIR AA Genotype in IVF Implantation Success? · completed
NCT06264206 — Effect of Immunomodulatory Treatment on IVF (in Vitro Fertilization) Outcomes in Patients With KIR AA Genotype · NA · completed
NCT05575739 — Evaluation of the Relationship Between Oxidative Stress and Human Reproduction · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06801652 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Calla IVF Center
Last refreshed: 30 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06801652.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing